• Beamtree secures $2m contract with Fakeeh Group in Saudi Arabia
• Strategic review underway to reset cost base and focus investment on highest-growth product lines
• Double-digit ARR growth guidance for FY26 withdrawn

Beamtree Holdings Limited (ASX:BMT) has announced a $2 million AUD contract with Fakeeh Care Group (Dr Soliman Fakeeh Hospitals) in Saudi Arabia, to be delivered over a 12-month period commencing May 2026. Under the agreement, Beamtree will provide coding, coding assurance and coding analytics support, both remotely and on-site, as the hospitals prepare for changes in clinical coding practices and funding reimbursement. This contract builds on Beamtree's growing presence in Saudi Arabia over the past four years, including projects such as a data quality audit of public hospitals and the development of the Kingdom's health information strategy. The company has also provided an interim update on its ongoing strategic review, announced in February 2026. The Board has taken decisive action to reset the cost base, with the exit run-rate as at 1 July 2026 aligning total cash operating costs with the company's revenue trajectory and positioning the business toward cash operating profit break-even, after product development costs, in FY27. Beamtree's product groups - Data Platforms, Coding Suite, and Diagnostics - have been assessed, and the Board has determined to concentrate investment behind its highest-growth product lines. Where product lines do not demonstrate a path to meaningful contribution within a reasonable timeframe, investment will be reduced or ceased. The company has also sharpened its sales pipeline disciplines to improve the quality and predictability of revenue conversion. However, with two months remaining in the financial year, several active opportunities are unlikely to close before the full-year results announcement, leading the Board to withdraw its guidance for double-digit ARR growth in FY26.

The next phase of the strategic review will complete decisions on product prioritisation and the Company's product and market development roadmap. The Board will provide its assessment of these matters and specific actions taken in the Company's FY26 full-year results announcement.